Literature DB >> 17593857

Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients.

M S Song1, I Mook-Jung, H J Lee, J Y Min, M H Park.   

Abstract

Alzheimer's disease (AD) is characterized by the deposition of senile plaques and neurofibrillary tangles in the brain. The presence of the amyloid-beta (Abeta) peptide in senile plaques seems to play a central role in the neuropathology of AD. Diagnosis of AD involves neuropsychological examinations or magnetic resonance imaging and, to date, a specific diagnostic marker indicating AD has not been found. This study analysed anti-Abeta antibodies from the serum of 153 patients with AD using an enzyme-linked immunosorbent assay method. The levels of anti-Abeta antibody from patients in the control group (n=193) were compared with those of patients with AD. Our results showed a significantly lower anti-Abeta antibody level in patients with AD than in the control group. These results showed that the anti-Abeta antibody level in serum could potentially be used to diagnose the presence of AD.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17593857     DOI： 10.1177/147323000703500303

Source DB:  PubMed          Journal:  J Int Med Res        ISSN： 0300-0605            Impact factor:   1.671


  10 in total

Review 1.  Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence.

Authors:  Richard Dodel; Frauke Neff; Carmen Noelker; Refik Pul; Yansheng Du; Michael Bacher; Wolfgang Oertel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

2.  Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.

Authors:  Madalina Maftei; Franka Thurm; Vera Maria Leirer; Christine A F von Arnim; Thomas Elbert; Michael Przybylski; Iris-Tatjana Kolassa; Marilena Manea
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

3.  ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Authors:  Andrea C Klaver; Mary P Coffey; Lynnae M Smith; David A Bennett; John M Finke; Loan Dang; David A Loeffler
Journal:  J Neuroinflammation       Date:  2011-08-09       Impact factor: 8.322

Review 4.  Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.

Authors:  Jacopo C DiFrancesco; Martina Longoni; Fabrizio Piazza
Journal:  Front Neurol       Date:  2015-09-25       Impact factor: 4.003

Review 5.  Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?

Authors:  Kurt A Jellinger; Bernd Janetzky; Johannes Attems; Elisabeth Kienzl
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

Review 6.  Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.

Authors:  Jin-A Mo; Ju-Hee Lim; Ah-Ram Sul; Min Lee; Young Chul Youn; Hee-Jin Kim
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

7.  Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.

Authors:  Sofia Söllvander; Frida Ekholm-Pettersson; Rose-Marie Brundin; Gabriel Westman; Lena Kilander; Staffan Paulie; Lars Lannfelt; Dag Sehlin
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 8.  Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications.

Authors:  Jianming Wu; Ling Li
Journal:  J Biomed Res       Date:  2016-01-02

Review 9.  Autoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases.

Authors:  Gabriela Kocurova; Jan Ricny; Saak V Ovsepian
Journal:  Theranostics       Date:  2022-03-28       Impact factor: 11.600

10.  Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.

Authors:  Madalina Maftei; Franka Thurm; Cathrin Schnack; Hayrettin Tumani; Markus Otto; Thomas Elbert; Iris-Tatjana Kolassa; Michael Przybylski; Marilena Manea; Christine A F von Arnim
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.